PUBLISHER: TechNavio | PRODUCT CODE: 2126173
PUBLISHER: TechNavio | PRODUCT CODE: 2126173
Global Lipid Nanoparticles Market 2026-2030
The global lipid nanoparticles market is forecasted to grow by USD 82503.4 thousand during 2025-2030, accelerating at a CAGR of 5.3% during the forecast period. The report on the global lipid nanoparticles market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by expansion of rna therapeutics and genetic medicine pipelines, rising prevalence of chronic diseases and oncology indications, advancements in microfluidic manufacturing and formulation scalability.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 5.1% |
| CAGR | 5.3% |
| Incremental Value | $82503.4 thousand |
Technavio's global lipid nanoparticles market is segmented as below:
By Type
- SLNs
- NLCs
- Others
By Product
- Ionizable lipids
- Phospho lipids
- Neutral lipids
- Others
By Application
- Therapeutics
- Research
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the shift toward extra-hepatic delivery and precision tissue targeting as one of the prime reasons driving the global lipid nanoparticles market growth during the next few years. Also, integration of ai in lipid chemistry design and expansion of regional gmp manufacturing infrastructure will lead to sizable demand in the market.
The report on the global lipid nanoparticles market covers the following areas:
- Global lipid nanoparticles market sizing
- Global lipid nanoparticles market forecast
- Global lipid nanoparticles market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global lipid nanoparticles market vendors that include Acuitas Therapeutics, Alnylam Pharmaceuticals Inc., Arcturus Therapeutics Holdings, BioNTech SE, BOCSCI Inc., Corden Pharma Intl. GmbH, Creative Biolabs, Curapath, Esco Aster Pte. Ltd., Evonik Industries AG, FUJIFILM Holdings Corp., Genevant Sciences Corp., GenScript Biotech Corp., Helix Biotech Inc., Merck KGaA, Moderna Inc., Northern RNA Inc., Pfizer Inc., Polymun, Precigenome LLC, Thermo Fisher Scientific Inc., Vernal Biosciences LLC. Also, the global lipid nanoparticles market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Product
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Lipid Nanoparticles Market 2020 - 2024
- Historic Market Size - Data Table on Global Lipid Nanoparticles Market 2020 - 2024 ($ thousand)
- 5.2 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ thousand)
- 5.3 Product segment analysis 2020 - 2024
- Historic Market Size - Product Segment 2020 - 2024 ($ thousand)
- 5.4 Application segment analysis 2020 - 2024
- Historic Market Size - Application Segment 2020 - 2024 ($ thousand)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ thousand)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ thousand)
6 Qualitative Analysis
- 6.1 Impact of AI on global lipid nanoparticles market
- 6.2 Impact of geopolitical conflicts on global lipid nanoparticles market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Type
- 8.1 Market segments
- 8.2 Comparison by Type
- 8.3 SLNs - Market size and forecast 2025-2030
- 8.4 NLCs - Market size and forecast 2025-2030
- 8.5 Others - Market size and forecast 2025-2030
- 8.6 Market opportunity by Type
- Market opportunity by Type ($ thousand)
9 Market Segmentation by Product
- 9.1 Market segments
- 9.2 Comparison by Product
- 9.3 Ionizable lipids - Market size and forecast 2025-2030
- 9.4 Phospho lipids - Market size and forecast 2025-2030
- 9.5 Neutral lipids - Market size and forecast 2025-2030
- 9.6 Others - Market size and forecast 2025-2030
- 9.7 Market opportunity by Product
- Market opportunity by Product ($ thousand)
10 Market Segmentation by Application
- 10.1 Market segments
- 10.2 Comparison by Application
- 10.3 Therapeutics - Market size and forecast 2025-2030
- 10.4 Research - Market size and forecast 2025-2030
- 10.5 Market opportunity by Application
- Market opportunity by Application ($ thousand)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Turkey - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 Colombia - Market size and forecast 2025-2030
- 12.6.7 South Africa - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ thousand)
- Data Tables on Market opportunity by geography ($ thousand)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Expansion of RNA therapeutics and genetic medicine pipelines
- Rising prevalence of chronic diseases and oncology indications
- Advancements in microfluidic manufacturing and formulation scalability
- 13.2 Market challenges
- Manufacturing scalability and batch-to-batch inconsistencies
- Stringent regulatory compliance and preclinical safety evaluation
- Ultra-cold chain logistics and thermal instability constraints
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Shift toward extra-hepatic delivery and precision tissue targeting
- Integration of AI in lipid chemistry design
- Expansion of regional GMP manufacturing infrastructure
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Alnylam Pharmaceuticals Inc.
- Alnylam Pharmaceuticals Inc. - Overview
- Alnylam Pharmaceuticals Inc. - Product / Service
- Alnylam Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.5 BioNTech SE
- BioNTech SE - Overview
- BioNTech SE - Product / Service
- BioNTech SE - Key offerings
- SWOT
- 15.6 BOCSCI Inc.
- BOCSCI Inc. - Overview
- BOCSCI Inc. - Product / Service
- BOCSCI Inc. - Key offerings
- SWOT
- 15.7 Corden Pharma Intl. GmbH
- Corden Pharma Intl. GmbH - Overview
- Corden Pharma Intl. GmbH - Product / Service
- Corden Pharma Intl. GmbH - Key offerings
- SWOT
- 15.8 Creative Biolabs
- Creative Biolabs - Overview
- Creative Biolabs - Product / Service
- Creative Biolabs - Key offerings
- SWOT
- 15.9 Curapath
- Curapath - Overview
- Curapath - Product / Service
- Curapath - Key offerings
- SWOT
- 15.10 Esco Aster Pte. Ltd.
- Esco Aster Pte. Ltd. - Overview
- Esco Aster Pte. Ltd. - Product / Service
- Esco Aster Pte. Ltd. - Key offerings
- SWOT
- 15.11 Evonik Industries AG
- Evonik Industries AG - Overview
- Evonik Industries AG - Business segments
- Evonik Industries AG - Key news
- Evonik Industries AG - Key offerings
- Evonik Industries AG - Segment focus
- SWOT
- 15.12 FUJIFILM Holdings Corp.
- FUJIFILM Holdings Corp. - Overview
- FUJIFILM Holdings Corp. - Business segments
- FUJIFILM Holdings Corp. - Key news
- FUJIFILM Holdings Corp. - Key offerings
- FUJIFILM Holdings Corp. - Segment focus
- SWOT
- 15.13 GenScript Biotech Corp.
- GenScript Biotech Corp. - Overview
- GenScript Biotech Corp. - Business segments
- GenScript Biotech Corp. - Key offerings
- GenScript Biotech Corp. - Segment focus
- SWOT
- 15.14 Helix Biotech Inc.
- Helix Biotech Inc. - Overview
- Helix Biotech Inc. - Product / Service
- Helix Biotech Inc. - Key offerings
- SWOT
- 15.15 Merck KGaA
- Merck KGaA - Overview
- Merck KGaA - Business segments
- Merck KGaA - Key news
- Merck KGaA - Key offerings
- Merck KGaA - Segment focus
- SWOT
- 15.16 Moderna Inc.
- Moderna Inc. - Overview
- Moderna Inc. - Product / Service
- Moderna Inc. - Key offerings
- SWOT
- 15.17 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
- 15.18 Thermo Fisher Scientific Inc.
- Thermo Fisher Scientific Inc. - Overview
- Thermo Fisher Scientific Inc. - Business segments
- Thermo Fisher Scientific Inc. - Key news
- Thermo Fisher Scientific Inc. - Key offerings
- Thermo Fisher Scientific Inc. - Segment focus
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
